guest ::
| Home > Publications database > Effects of Ketamine and Midazolam on resting state connectivity and comparison with ENIGMA connectivity deficit patterns in schizophrenia > print |
| Home > Publications database > Effects of Ketamine and Midazolam on resting state connectivity and comparison with ENIGMA connectivity deficit patterns in schizophrenia > print |
| 001 | 865828 | ||
| 005 | 20210130003150.0 | ||
| 024 | 7 | _ | |a 10.1002/hbm.24838 |2 doi |
| 024 | 7 | _ | |a 1065-9471 |2 ISSN |
| 024 | 7 | _ | |a 1097-0193 |2 ISSN |
| 024 | 7 | _ | |a 2128/23996 |2 Handle |
| 024 | 7 | _ | |a altmetric:69068293 |2 altmetric |
| 024 | 7 | _ | |a pmid:31633254 |2 pmid |
| 024 | 7 | _ | |a WOS:000491156400001 |2 WOS |
| 037 | _ | _ | |a FZJ-2019-05119 |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Adhikari, Bhim M. |0 P:(DE-HGF)0 |b 0 |
| 245 | _ | _ | |a Effects of Ketamine and Midazolam on resting state connectivity and comparison with ENIGMA connectivity deficit patterns in schizophrenia |
| 260 | _ | _ | |a New York, NY |c 2020 |b Wiley-Liss |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1579705204_19971 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a NIH. Grant Numbers: T32MH067533, R01MH085646, R01DA027680, R01MH112180, R01EB015611, U01MH108148, U54EB020403 |
| 520 | _ | _ | |a Subanesthetic administration of ketamine is a pharmacological model to elicit positiveand negative symptoms of psychosis in healthy volunteers. We used resting statepharmacological functional MRI (rsPhfMRI) to identify cerebral networks affected by ketamineand compared them to the functional connectivity (FC) in schizophrenia. Ketamine can producesedation and we contrasted its effects with the effects of the anxiolytic drug midazolam.Thirty healthy male volunteers (age=19-37 years) underwent a randomized, three-way,cross-over study consisting of three imaging sessions, with 48 hours between sessions. A sessionconsisted of a control period followed by infusion of placebo or ketamine or midazolam. TheENIGMA rsfMRI pipeline was used to derive two long distance (seed-based and dualregression)and one local (regional homogeneity, ReHo) FC measures. Ketamine inducedsignificant reductions in the connectivity of the salience network (Cohen’s d:1.13±0.28,p=4.0×10-3), auditory network (d: 0.67±0.26, p=0.04) and default mode network (DMN,d:0.63±0.26, p=0.05). Midazolam significantly reduced connectivity in the DMN (d:0.77±0.27,p=0.03). The effect sizes for ketamine for resting networks showed a positive correlation(r=0.59, p=0.07) with the effect sizes for schizophrenia related deficits derived from ENIGMA’sstudy of 261 patients and 327 controls. Effect sizes for midazolam were not correlated with theschizophrenia pattern (r=-0.17, p=0.65). The subtraction of ketamine and midazolam patternsshowed a significant positive correlation with the pattern of schizophrenia deficits (r=0.68,p=0.03).RsPhfMRI reliably detected the shared and divergent pharmacological actions ofketamine and midazolam on cerebral networks. The pattern of disconnectivity produced byketamine was positively correlated with the pattern of connectivity deficits observed inschizophrenia, suggesting a brain functional basis for previously poorly understood effects of thedrug. |
| 536 | _ | _ | |a 573 - Neuroimaging (POF3-573) |0 G:(DE-HGF)POF3-573 |c POF3-573 |f POF III |x 0 |
| 536 | _ | _ | |a 571 - Connectivity and Activity (POF3-571) |0 G:(DE-HGF)POF3-571 |c POF3-571 |f POF III |x 1 |
| 588 | _ | _ | |a Dataset connected to CrossRef |
| 700 | 1 | _ | |a Dukart, Juergen |0 P:(DE-Juel1)177772 |b 1 |
| 700 | 1 | _ | |a Hipp, Joerg F. |0 P:(DE-HGF)0 |b 2 |
| 700 | 1 | _ | |a Forsyth, Anna |0 P:(DE-HGF)0 |b 3 |
| 700 | 1 | _ | |a McMillan, Rebecca |0 P:(DE-HGF)0 |b 4 |
| 700 | 1 | _ | |a Muthukumaraswamy, Suresh D. |0 P:(DE-HGF)0 |b 5 |
| 700 | 1 | _ | |a Ryan, Meghann C. |0 P:(DE-HGF)0 |b 6 |
| 700 | 1 | _ | |a Elliot Hong, L. |0 P:(DE-HGF)0 |b 7 |
| 700 | 1 | _ | |a Eickhoff, Simon |0 P:(DE-Juel1)131678 |b 8 |u fzj |
| 700 | 1 | _ | |a Jahanshad, Neda |0 P:(DE-HGF)0 |b 9 |
| 700 | 1 | _ | |a Thompson, Paul M. |0 P:(DE-HGF)0 |b 10 |
| 700 | 1 | _ | |a Rowland, Laura M. |0 P:(DE-HGF)0 |b 11 |
| 700 | 1 | _ | |a Kochunov, Peter |0 P:(DE-HGF)0 |b 12 |e Corresponding author |
| 773 | _ | _ | |a 10.1002/hbm.24838 |g p. hbm.24838 |0 PERI:(DE-600)1492703-2 |n 3 |p 767-778 |t Human brain mapping |v 41 |y 2020 |x 1065-9471 |
| 856 | 4 | _ | |y OpenAccess |u https://juser.fz-juelich.de/record/865828/files/Adhikari_et_al-2020-Human_Brain_Mapping.pdf |
| 856 | 4 | _ | |y OpenAccess |x pdfa |u https://juser.fz-juelich.de/record/865828/files/Adhikari_et_al-2020-Human_Brain_Mapping.pdf?subformat=pdfa |
| 909 | C | O | |o oai:juser.fz-juelich.de:865828 |p openaire |p open_access |p VDB |p driver |p dnbdelivery |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 8 |6 P:(DE-Juel1)131678 |
| 913 | 1 | _ | |a DE-HGF |b Key Technologies |l Decoding the Human Brain |1 G:(DE-HGF)POF3-570 |0 G:(DE-HGF)POF3-573 |2 G:(DE-HGF)POF3-500 |v Neuroimaging |x 0 |4 G:(DE-HGF)POF |3 G:(DE-HGF)POF3 |
| 913 | 1 | _ | |a DE-HGF |b Key Technologies |l Decoding the Human Brain |1 G:(DE-HGF)POF3-570 |0 G:(DE-HGF)POF3-571 |2 G:(DE-HGF)POF3-500 |v Connectivity and Activity |x 1 |4 G:(DE-HGF)POF |3 G:(DE-HGF)POF3 |
| 914 | 1 | _ | |y 2020 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |
| 915 | _ | _ | |a Creative Commons Attribution CC BY 4.0 |0 LIC:(DE-HGF)CCBY4 |2 HGFVOC |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b HUM BRAIN MAPP : 2017 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0110 |2 StatID |b Science Citation Index |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0111 |2 StatID |b Science Citation Index Expanded |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |
| 915 | _ | _ | |a OpenAccess |0 StatID:(DE-HGF)0510 |2 StatID |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0310 |2 StatID |b NCBI Molecular Biology Database |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |
| 920 | _ | _ | |l yes |
| 920 | 1 | _ | |0 I:(DE-Juel1)INM-7-20090406 |k INM-7 |l Gehirn & Verhalten |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a UNRESTRICTED |
| 980 | _ | _ | |a I:(DE-Juel1)INM-7-20090406 |
| 980 | 1 | _ | |a FullTexts |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|